Avid Bioservices to Become Private Under New Ownership
Avid Bioservices, Inc. (NASDAQ: CDMO) has made significant strides in the biopharmaceutical sector, establishing itself as a trusted biologics contract development and manufacturing organization. Recent developments reveal that the company is set to be acquired by GHO Capital Partners LLP and Ampersand Capital Partners in a landmark transaction valued at around $1.1 billion. This all-cash deal marks an important turning point for Avid, which has been dedicated to improving patient lives through high-quality development and manufacturing services.
Details of the Acquisition
The merger agreement states that both GHO and Ampersand will acquire all outstanding shares held by Avid’s stockholders for $12.50 per share. This figure represents a considerable 13.8% premium over Avid’s closing share price prior to the announcement, showcasing the shareholders' immediate benefits from this strategic decision. This transaction not only highlights a growth opportunity for Avid but also demonstrates the confidence GHO and Ampersand have in the company’s future potential.
Leadership Insights
Nick Green, the President and CEO of Avid Bioservices, expressed excitement regarding the merger, indicating that it comes at a pivotal moment for the company's development. The leadership team evaluated various options and concluded that the acquisition by experienced partners like GHO and Ampersand aligns perfectly with their vision for the future. Such a partnership is expected to leverage extensive industry knowledge and capital to further enhance Avid's offerings to clients.
GHO Capital’s Perspective
Alan MacKay and Mike Mortimer, Managing Partners at GHO, stated their enthusiasm about the acquisition, emphasizing their commitment to improving healthcare accessibility and efficiency through high-quality manufacturing. They acknowledged Avid’s strong market presence and investment in capacity, positioning them for accelerated growth in the biopharmaceutical sector.
Future Outlook for Avid
As the acquisition progresses, it is essential to note that Avid will continue to operate independently until its tiresome closure, which is anticipated to occur in the first quarter of the next year, pending all necessary approvals. Upon completion, Avid will still operate using its established name and brand, preserving its identity while enhancing its operational capabilities with the support of its new owners.
Strategic Advisors in the Acquisition
Various prominent advisory firms are involved in this transaction. Avid is supported by Moelis & Company as its exclusive financial advisor, while Cooley LLP serves as its legal counsel. GHO and Ampersand are also backed by William Blair & Company, LLC, and Ropes & Gray LLP. Such rigorous oversight ensures the transaction adheres to best practices, aiming for the best outcome for all parties involved.
About Avid Bioservices and Its Services
Founded over three decades ago, Avid has honed its expertise in providing comprehensive process development and CGMP clinical and commercial manufacturing services. The company prides itself on its robust regulatory track record and its expansive range of services including bulk packaging and stability testing. Their dedication to advancing biopharmaceutical manufacturing ensures their clients receive excellent support throughout the product lifecycle.
About GHO Capital and Ampersand Capital Partners
Global Healthcare Opportunities (GHO) and Ampersand Capital Partners are notable players in the healthcare investment landscape, focusing on high-growth opportunities. Ampersand Capital is particularly recognized for its middle-market investments in the healthcare sector, where it applies its wealth of experience to foster innovative companies that can enhance healthcare delivery.
Frequently Asked Questions
What is the value of the Avid Bioservices acquisition?
The acquisition is valued at approximately $1.1 billion, demonstrating the partners' commitment to reinvesting in the company’s future.
Who are the new owners of Avid Bioservices?
The new owners are GHO Capital Partners LLP and Ampersand Capital Partners, both of which have extensive experience in the healthcare investment sector.
What will happen to Avid’s stock after the acquisition?
Once the acquisition is finalized, Avid's common stock will be delisted from public exchanges, transitioning to private ownership.
How does this acquisition benefit Avid Bioservices?
The merger provides Avid access to additional capital and expertise, enabling it to expand its service offerings and enhance operations.
What is the projected timeline for the acquisition completion?
The transaction is expected to close in the first quarter of next year, subject to customary closing conditions and approvals.
